Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
16 03 2021
Historique:
entrez: 17 3 2021
pubmed: 18 3 2021
medline: 23 3 2021
Statut: epublish

Résumé

To determine the extent and nature of changes in utilisation of healthcare services during COVID-19 pandemic. Systematic review. Eligible studies compared utilisation of services during COVID-19 pandemic to at least one comparable period in prior years. Services included visits, admissions, diagnostics and therapeutics. Studies were excluded if from single centres or studied only patients with COVID-19. PubMed, Embase, Cochrane COVID-19 Study Register and preprints were searched, without language restrictions, until 10 August, using detailed searches with key concepts including COVID-19, health services and impact. Risk of bias was assessed by adapting the Risk of Bias in Non-randomised Studies of Interventions tool, and a Cochrane Effective Practice and Organization of Care tool. Results were analysed using descriptive statistics, graphical figures and narrative synthesis. Primary outcome was change in service utilisation between prepandemic and pandemic periods. Secondary outcome was the change in proportions of users of healthcare services with milder or more severe illness (eg, triage scores). 3097 unique references were identified, and 81 studies across 20 countries included, reporting on >11 million services prepandemic and 6.9 million during pandemic. For the primary outcome, there were 143 estimates of changes, with a median 37% reduction in services overall (IQR -51% to -20%), comprising median reductions for visits of 42% (-53% to -32%), admissions 28% (-40% to -17%), diagnostics 31% (-53% to -24%) and for therapeutics 30% (-57% to -19%). Among 35 studies reporting secondary outcomes, there were 60 estimates, with 27 (45%) reporting larger reductions in utilisation among people with a milder spectrum of illness, and 33 (55%) reporting no difference. Healthcare utilisation decreased by about a third during the pandemic, with considerable variation, and with greater reductions among people with less severe illness. While addressing unmet need remains a priority, studies of health impacts of reductions may help health systems reduce unnecessary care in the postpandemic recovery. CRD42020203729.

Identifiants

pubmed: 33727273
pii: bmjopen-2020-045343
doi: 10.1136/bmjopen-2020-045343
pmc: PMC7969768
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e045343

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: RM has helped organise the Preventing Overdiagnosis international scientific conferences.

Références

Int J Health Policy Manag. 2020 Oct 01;9(10):419-422
pubmed: 32610730
BMJ. 2013 Jul 02;347:f4247
pubmed: 23820022
Can J Cardiol. 2020 Jul;36(7):1152-1155
pubmed: 32447060
JAMA Intern Med. 2020 Oct 1;180(10):1334-1335
pubmed: 32744611
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
J Am Coll Radiol. 2020 Sep;17(9):1086-1095
pubmed: 32717183
BMJ. 2019 Nov 5;367:l6317
pubmed: 31690578
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
JAMA. 2020 Jul 7;324(1):96-99
pubmed: 32501493
J Am Coll Radiol. 2020 Jul;17(7):865-872
pubmed: 32425710
Intern Emerg Med. 2020 Aug;15(5):825-833
pubmed: 32507926
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMC Health Serv Res. 2008 Nov 06;8:228
pubmed: 18990210
BMJ. 2020 Jul 14;370:m2752
pubmed: 32665257
Scand J Gastroenterol. 2020 Jul;55(7):870-876
pubmed: 32615891
Euro Surveill. 2020 May;25(19):
pubmed: 32431288
Psychiatry Clin Neurosci. 2020 Oct;74(10):557-559
pubmed: 32609417
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
J Am Med Inform Assoc. 2020 Jul 1;27(7):1132-1135
pubmed: 32324855
PLoS Med. 2013;10(4):e1001419
pubmed: 23585737
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):699-704
pubmed: 32525856
Arch Dis Child. 2020 Jul;105(7):704-706
pubmed: 32461213
Lancet Public Health. 2020 Aug;5(8):e437-e443
pubmed: 32473113
JAMA. 2012 Apr 11;307(14):1513-6
pubmed: 22419800

Auteurs

Ray Moynihan (R)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia raymoynihan@bond.edu.au.

Sharon Sanders (S)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Zoe A Michaleff (ZA)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Anna Mae Scott (AM)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Justin Clark (J)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Emma J To (EJ)

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Mark Jones (M)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Eliza Kitchener (E)

Faculty of Medicine, Dentistry and Health, Griffith University, Brisbane, Queensland, Australia.

Melissa Fox (M)

Health Consumers Queensland, Adelaide, Queensland, Queensland.

Minna Johansson (M)

Cochrane Sustainable Healthcare Field, Lund, Sweden.

Eddy Lang (E)

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Anne Duggan (A)

Australian Commission on Safety and Quality in Healthcare, Sydney, New South Wales, Australia.

Ian Scott (I)

Internal Medicine and Clinical Epidemiology, Princess Alexander Hospital, Brisbane, Queensland, Australia.

Loai Albarqouni (L)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH